hsk31679
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Haisco Pharmaceutical Group Co., Ltd.Phase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 89/ 100
Competitive context
130 Active assets in the MASH - Metabolic Dysfunction-Associated Steatohepatitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Resmetirom City University of New York | Phase 4 | BBB |
Pentoxifylline Al-Azhar University | Phase 4 | BBB |
Pioglitazone Badr University | Phase 4 | BBB |
Semaglutide Cascade Pharmaceuticals, Inc | Phase 4 | BBB |
Firsocostat Gilead Sciences | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
hsk31679 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →